Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Seres Therapeutics, Inc. | mcrb-ex322_84.htm |
| EX-32.1 - EX-32.1 - Seres Therapeutics, Inc. | mcrb-ex321_10.htm |
| EX-31.2 - EX-31.2 - Seres Therapeutics, Inc. | mcrb-ex312_83.htm |
| EX-31.1 - EX-31.1 - Seres Therapeutics, Inc. | mcrb-ex311_7.htm |
| EX-21.1 - EX-21.1 - Seres Therapeutics, Inc. | mcrb-ex211_9.htm |
| EX-10.14 - EX-10.14 - Seres Therapeutics, Inc. | mcrb-ex1014_133.htm |
| EX-4.3 - EX-4.3 - Seres Therapeutics, Inc. | mcrb-ex43_134.htm |
| 10-K - 10-K - Seres Therapeutics, Inc. | mcrb-10k_20191231.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-230092, 333-223514, 333-210171 and 333-205253) and Form S-3 (No. 333-216735) of Seres Therapeutics, Inc. of our report dated March 2, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 2, 2020
1